BrianKeithTurpinDO
Pediatric Hematology & Oncology • Cincinnati, OHAssistant Professor, Pediatrics, University of Cincinnati College of Medicine
Dr. Turpin is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3333 Burnet Ave
Cincinnati, OH 45229Phone+1 513-636-3381Fax+1 513-636-3549
Education & Training
Cincinnati Children's Hospital Medical CenterFellowship, Pediatric Hematology/Oncology, 2009 - 2012- Cincinnati Children's Hospital Medical CenterResidency, Pediatrics, 2006 - 2009
Kansas City University of Medicine and Biosciences College of Osteopathic MedicineClass of 2006
Certifications & Licensure
OH State License 2006 - 2025- American Board of Pediatrics Pediatric Hematology-Oncology
Clinical Trials
- A Pilot Study of the Addition of Bevacizumab to VOIT Regimen for Relapsed/Refractory Pediatric Solid Tumors Start of enrollment: 2008 Oct 01
- Pembrolizumab in Combination With Decitabine and Hypofractionated Index Lesion Radiation in Pediatrics and Young Adults Start of enrollment: 2018 Feb 12
- VITAS: Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid Tumors Start of enrollment: 2023 Apr 18
Roles: Principal Investigator, Contact
Publications & Presentations
PubMed
- 1604 citationsEfficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and ChildrenAlexander Drilon, Theodore W. Laetsch, Shivaani Kummar, Steven G. DuBois, Ulrik Lassen
The New England Journal of Medicine. 2018-02-21 - 348 citationsLarotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study.Theodore W. Laetsch, Steven G. DuBois, Leo Mascarenhas, Brian Turpin, Noah Federman
The Lancet. Oncology. 2018-05-01 - 19 citationsResults of a Randomized, Double-Blinded, Placebo-Controlled, Phase 2.5 Study of Saracatinib (AZD0530), in Patients with Recurrent Osteosarcoma Localized to the Lung.Kristin Baird, John Glod, Seth M. Steinberg, Denise K. Reinke, Joseph G. Pressey
Sarcoma. 2020-04-30
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
